Leukemia

Combined with chemotherapy, blinatumomab appears tolerable and beneficial in a subgroup of pediatric patients with B-cell acute lymphoblastic leukemia in first relapse but does not yield better survival outcomes in the overall population.

A comprehensive review of chronic myeloid leukemia olverembatinib data led by expert Kebede Begna, MD, from the Mayo Clinic team.

Following a review of the retrospective analysis of PACE, experts reflect on its importance in understanding the risk of arterial occlusive events with ponatinib.

Alan Skarbnik, MD, and Ryan Jacobs, MD, review efficacy data from the indirect comparison study of acalabrutinib versus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia.

Focused discussion on key clinical trial data behind currently available BTK inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia.

The potential reduction in relapse in patients with unresectable chronic lymphocytic leukemia appears to happen regardless of minimal residual disease status 3 months post-treatment and immunoglobulin heavy-chain variable region mutational status.

A focused discussion led by expert Abhishek Mangaonkar, MBBS, on a retrospective analysis elucidating arterial occlusive events within the PACE study.

Expert perspectives from the Mayo Clinic and UT Southwestern teams on applications of the OPTIC study and optimal ponatinib dosing in chronic myeloid leukemia.

JZP458 is part of a multi-agent chemotherapy regimen for lymphoblastic lymphoma and acute lymphoblastic leukemia, and can be used for adult and pediatric patients.

Data from a phase 1b dose escalation and expansion study highlight an encouraging duration of remission using APVO436 plus venetoclax and azacitidine in patients with acute myeloid leukemia.

Key opinion leader Kebede Begna, MD, reviews data from the OPTIC study focused on ponatinib dosing in chronic-phase CML.

Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in chronic myeloid leukemia.

Mikkael A. Sekeres, MD, discusses how data from the phase 3 QuANTUM-First trial may advance the treatment field for patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

Data from the phase 3 QuANTUM-First trial support the FDA’s approval of quizartinib for managing FLT3-ITD–positive acute myeloid leukemia.

Findings from a phase 2 study may inform the design of future trials assessing fecal microbiota transplants in patients with acute myeloid leukemia.

A Matching-Adjusted Indirect Comparison of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Factors including measurable residual disease and CAR T-cell expansion appear to predict duration of response following JCAR014 in those with relapsed or refractory chronic lymphocytic leukemia in a phase 1/2 trial.

The agent will be evaluated in a phase 1 study for patients with several myeloid malignancies, in which investigators will identify a recommended phase 2 dose.

Pediatric patients with acute lymphoblastic leukemia and have KMT2A rearrangements were evaluated in a recent study published in the British Journal of Haematology.

A study regarding next-generation sequencing evaluated minimal residual disease in patients with acute myeloid leukemia.

The combination of venetoclax and ibrutinib may yield long-lasting treatment-free remission among patients with high-risk chronic lymphocytic leukemia.

Blinatumomab has been granted full approval by the FDA for patients with B-cell acute lymphoblastic leukemia and minimal residual disease of 0.01% or more.

Investigators pause their evaluation of SC-DARIC33 in pediatric relapsed/refractory acute myeloid leukemia following a grade 5 serious adverse effect in the phase 1 PLAT-08 trial.

Investigators identify only 1 death related to treatment with acalabrutinib among older, frail patients with chronic lymphocytic leukemia in the phase 2 CLL-FRAIL trial.

Adding blinatumomab to Interfant-06 chemotherapy appears to be feasible and safe in the treatment infants with acute lymphoblastic leukemia in a phase 2 trial.